Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors

Pellé, Gaëlle; Shweke, Nasim; Huyen, Jean–Paul Duong Van; Tricot, L.; Hessaine, Sadika; Frémeaux‐Bacchi, Véronique; Hiesse, C; Delahousse, Michel

doi:10.1053/j.ajkd.2010.11.030

Cited by 75 publications

(68 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean follow-up duration was 20 ± 4.5 months (range, [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. No eyes developed retinal detachment during the follow-up period.…”

Section: Resultsmentioning

confidence: 99%

“…Proteinuria following ranibizumab injection may be incidental. However, nephropathy has previously been reported after intravitreal injections of both bevacizumab and ranibizumab for exudative agere lated macular degeneration (25,26) . Pelle et al (26) proposed excessive VEGF expression by podocytes in the normal kidney as the mechanism underlying proteinuria.…”

Section: Discussionmentioning

confidence: 98%

“…However, nephropathy has previously been reported after intravitreal injections of both bevacizumab and ranibizumab for exudative agere lated macular degeneration (25,26) . Pelle et al (26) proposed excessive VEGF expression by podocytes in the normal kidney as the mechanism underlying proteinuria. Dysregulation of VEGF expression within the glomerulus has been associated with a wide range of renal diseases, many of which cause significant hypertension and varying amounts of proteinuria that may occur within weeks to months after administration intravitreal anti-VEGF therapy (25,26) .…”

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Erol

Çoban

Sarı³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose:To compare the efficacy of intravitreal ranibizumab and bevacizumab treatment for type 1 retinopathy of prematurity (ROP). Methods: 36 eyes of 20 patients with type 1 ROP who received anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections between August 2011 and February 2013 were retrospectively evaluated. Fifteen eyes of 8 patients received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 patients received 0.625 mg be vacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. Results: The mean gestation time was 26.2 ± 2.7 weeks in group 1 patients and 27.1 ± 2.5 weeks in group 2 patients. No statistical difference in the time of gestation was observed between the two groups. The mean follow-up period was 20 ± 4.5 months. Laser photocoagulation was performed in 6 of 15 eyes from group 1 and 2 of 21 eyes from group 2. No eyes developed retinal detachment during the follow-up period. Conclusion: Ranibizumab and bevacizumab showed an efficacy in the treatment of type 1 ROP. The incidence of disease relapse was higher in eyes which received ranibizumab. Further randomized, controlled clinical trials are required to compare the efficacy of ranibizumab and bevacizumab. Keywords

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Erol

Çoban

Sarı³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…58 Rare systemic events include formed visual hallucinations, 59 erectile dysfunction, 60 and acute decrease in kidney function. 61 The causative role of anti-VEGF agents in these cases remains to be established.…”

Section: Methodsmentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

731

549

View full text Add to dashboard Cite

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

show abstract

“…The pharmacokinetics of bevacizumab differ from that of ranibizumab due to its molecular structure, including the Fc fragment, and it has a longer half-life in the systemic circulation, which might explain signals for possible differences in systemic safety profiles. Systemic side effects of anti-VEGF treatment overall are rare; however, it is still a matter of debate whether treatment with anti-VEGF could increase the risk of thromboembolic events (59) or cause kidney toxicity (60). While in the CATT study, there were no differences in rates of death or arteriothrombotic events, a higher rate of serious adverse events was reported for bevacizumab-treated patients (55).…”

Section: Current Treatments Unmet Needs and Future Directionsmentioning

confidence: 98%

Recent developments in the treatment of age-related macular degeneration

Holz¹,

Schmitz-Valckenberg²,

2014

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a common cause of visual loss in the elderly, with increasing prevalence due to increasing life expectancy. While the introduction of anti-VEGF therapy has improved outcomes, there are still major unmet needs and gaps in the understanding of underlying biological processes. These include early, intermediate, and atrophic disease stages. Recent studies have assessed therapeutic approaches addressing various disease-associated pathways, including complement inhibitors. Drug-delivery aspects are also relevant, as many agents have to be administered repeatedly. Herein, relevant pathogenetic factors and underlying mechanisms as well as recent and potential therapeutic approaches are reviewed.

show abstract

Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors

Cited by 75 publications

References 18 publications

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Recent developments in the treatment of age-related macular degeneration

Contact Info

Product

Resources

About